NeuroSense Therapeutics (NASDAQ:NRSN) vs. Phathom Pharmaceuticals (NASDAQ:PHAT) Head-To-Head Analysis

NeuroSense Therapeutics (NASDAQ:NRSN) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Earnings & Valuation

This table compares NeuroSense Therapeutics and Phathom Pharmaceuticals’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.28 million	($0.83)	-1.48
Phathom Pharmaceuticals	$680,000.00	869.19	-$201.59 million	($3.88)	-2.60

NeuroSense Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NeuroSense Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Profitability

This table compares NeuroSense Therapeutics and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	-678.59%	-207.30%
Phathom Pharmaceuticals	N/A	N/A	-63.40%

Analyst Ratings

This is a summary of recent ratings and price targets for NeuroSense Therapeutics and Phathom Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	0	0	1	0	3.00
Phathom Pharmaceuticals	0	1	4	0	2.80

Phathom Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 117.82%. Given Phathom Pharmaceuticals’ higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than NeuroSense Therapeutics.

Institutional and Insider Ownership

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.